Mobile Developers Now Get Greater Control of Their Revenue, Ownership of Their Data, and Direct-to-Consumer Capabilities With New Features for Xsolla’s Leading Web Shop
14.8.2025 19:19:00 CEST | Business Wire | Press Release
Xsolla, a leading global video game commerce company, announces significant updates to its leading Web Shop solution for mobile games, a modular solution that enables mobile developers to quickly generate direct-to-consumer stores in minutes or build fully customized storefronts with advanced features.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250813375229/en/
(Graphic: Xsolla)
As developers face rising user acquisition costs and development expenses, varying regulations across regions, and high in-app fees, Xsolla Web Shop offers a strategic edge: a frictionless way to convert players into paying customers, retain them longer, expand monetization beyond the platforms, and operate LiveOps with more automation and reduced overhead.
Key benefits of the easy plug-in new features in Xsolla Web Shop include:
- Automated and simplified operations. Cut operational overhead by up to 50% using real-time catalog sync, dynamic bundles, and streamlined JSON import.
- Higher retention and lifetime value. Boost player retention by 15%+ and ARPPU by 20%+ with features designed to keep users coming back:
- Adaptive Offer Chains that evolve with each purchase to enhance satisfaction and increase spending.
- Subscriptions that deliver recurring benefits and long-term value.
- Discord Bot that brings commerce capabilities directly into Discord servers to mirror the Web Shop experience through messages and server channels.
- Social Quests that reward players for visiting a Discord server, viewing a YouTube video, and sharing events.
- Increased conversions: See over 30% conversion increase with upgraded browser-based PWA push notifications that re-engage players with event alerts, timed offers, and personal messages, right in their browser.
- Higher margins with Buy Button*. Earn up to 25% higher margins on U.S. iOS transactions by letting players pay directly from their game via a browser using a seamless, one-tap checkout.
- Optimized ROI with the widest coverage of MMPs (mobile measurement partners). Seamless integration to Appsflyer, Adjust (available now), and Singular (coming soon), enabling better attribution, campaign optimization, and performance tracking.
- Faster time-to-market. Decrease your time-to-market by 50% with a no-code, fully custom Web Shop built from custom blocks, widgets, and modules with the flexibility of Headless Storefront SDK.
For a complete list of new features and improvements, check out our Release Notes.
“With the new updates to Web Shop, we're giving developers a powerful extension of their in-game monetization,” said Chris Hewish, President at Xsolla. “It’s designed to perform, built for LiveOps, and aligned with the latest market dynamics. It's not just about long-term revenue, it's about operating smarter and maximizing the player relationship.”
With over 600 Web Shops launched globally, Xsolla’s partners have collectively demonstrated their effectiveness at scaling direct sales and creating lasting revenue streams outside traditional app store ecosystems. The new updates to Xsolla Web Shop provide studios with an even quicker and more seamless way to earn more substantial and long-term revenue, while retaining a larger share of every dollar that comes in.
With this release, Xsolla positions the Web Shop and the recently launched Buy Button for Mobile Games as a revenue stream and a foundational component of every mobile game’s LiveOps and D2C strategy.
To learn more or launch your Web Shop, visit www.xsolla.com/web-shop or talk to an expert.
For a complete list of enhancements and developer tools, visit: xsolla.pro/rws25nextlevelwebshop
*April 30, 2025 U.S. District Court ruling
About Xsolla
Xsolla is a leading global video game commerce company with a robust and powerful set of tools and services designed specifically for the industry. Since its founding in 2005, Xsolla has helped thousands of game developers and publishers of all sizes fund, market, launch, and monetize their games globally and across multiple platforms. As an innovative leader in game commerce, Xsolla’s mission is to solve the inherent complexities of global distribution, marketing, and monetization to help our partners reach more geographies, generate more revenue, and create relationships with gamers worldwide. Headquartered and incorporated in Los Angeles, California, with offices in London, Berlin, Seoul, Beijing, Kuala Lumpur, Raleigh, Tokyo, Montreal, and cities around the world.
For more information, visit xsolla.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20250813375229/en/
Contacts
Media Contact
Derrick Stembridge
Vice President of Global Public Relations, Xsolla
d.stembridge@xsolla.com
(c) 2024 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Phase 3 RAINIER Results Supporting Best-in-Class Potential of Povetacicept in IgA Nephropathy Published in the New England Journal of Medicine and Presented at the American Society of Nephrology Kidney Week 202623.10.2026 19:42:00 CEST | Press Release
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the publication of Phase 3 RAINIER results for povetacicept in the New England Journal of Medicine (NEJM), presentation of these data at the American Society of Nephrology (ASN) Kidney Week 2026 in Denver, Colorado, and advancement of the povetacicept clinical research program in IgAN. Vertex will also host an investor event during ASN on October 23 at 6:15-7 p.m. MDT (8:15-9 p.m. EDT). Further details are below. Data being presented include a pre-specified Week 36 interim analysis of the ongoing Phase 3 RAINIER trial of povetacicept, an engineered fusion protein and dual inhibitor of the BAFF (B cell activating factor) and APRIL (a proliferation inducing ligand) cytokines, in immunoglobulin A nephropathy (IgAN). RAINIER met its primary endpoint, with povetacicept achieving a 52.0% reduction from baseline in proteinuria at Week 36 and a statistically significant and clinically meaningful 49.8% reduction versus placebo (
Lifezone Metals Confirms Advanced Negotiations with Orion CMC on Kabanga Nickel Project23.10.2026 16:19:00 CEST | Press Release
Lifezone Metals Limited (NYSE: LZM) notes comments made today by Oskar Lewnowski, Founder and Group Chief Executive of Orion Resource Partners, in an interview with Bloomberg Television regarding the Company’s Kabanga Nickel Project in Tanzania. In response to inbound inquiries from media outlets and investors following the interview, the Company can confirm that negotiations with Orion Critical Mineral Consortium (Orion CMC) regarding a significant equity investment into the Kabanga Nickel Project are at an advanced stage. The Orion CMC is a global investment platform launched by Orion Resource Partners in partnership with the U.S. International Development Finance Corporation (DFC) and Abu Dhabi's sovereign investor ADQ. As previously announced, the Company has been running a competitive process, led by Standard Chartered Bank, to secure a strategic investment into the Kabanga Nickel Project. Social Media LinkedIn | X | YouTube About Lifezone Metals Lifezone Metals (NYSE: LZM) is com
BeOne Medicines Reports Sustained Survival Benefit with TEVIMBRA-ZIIHERA Combination in First-Line HER2+ Gastroesophageal Cancer23.10.2026 16:15:00 CEST | Press Release
BeOne Medicines Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced new survival results from the planned second interim analysis (IA2) and final formal analysis of the Phase 3 HERIZON-GEA-01 trial, further confirming the benefit of TEVIMBRA® (tislelizumab) plus ZIIHERA® (zanidatamab) and chemotherapy as first-line treatment for patients with HER2-positive locally advanced or metastatic gastroesophageal adenocarcinoma (GEA). The results will be presented today as a late-breaking abstract during a rapid oral session at the European Society for Medical Oncology (ESMO) Congress 2026 in Madrid, Spain (LBA79). Mark Lanasa, M.D., Ph.D., Chief Medical Officer, Solid Tumors at BeOne, said: “Following the U.S. approval in August, these longer-term data provide further evidence supporting TEVIMBRA plus ZIIHERA and chemotherapy as the new standard of care in all first-line HER2-positive advanced gastroesophageal adenocarcinoma patients, regardless of PD-L1 sta
inDrive and Pony.ai Announce Collaboration to Explore Autonomous Mobility in Kazakhstan Built on NVIDIA Hyperion23.10.2026 15:00:00 CEST | Press Release
inDrive, the global mobility and delivery platform, today announced it has signed a memorandum of understanding (MOU) with NVIDIA and Pony.ai, a global leader in the large-scale commercialization of autonomous driving technology, to explore the future of autonomous ride-hailing. Kazakhstan will serve as the first test market. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261023143469/en/ inDrive partners with Pony.ai and NVIDIA to explore autonomous mobility in Kazakhstan Kazakhstan was chosen first for its regulatory readiness following the creation of the country’s first structured legal framework for driverless transport, as part of its “Year of Digitalization and Artificial Intelligence.” Combined with Kazakhstan’s position as a leading Central Asian economy, this gives the companies a clear basis to assess autonomous ride-hailing in practice. The three companies will evaluate the technical, operational, regulatory and
Brenus Pharma's Novel In Vivo Immunotherapy STC-1010 Shows Safety, Activating T Cells in First-Line MSS Metastatic Colorectal Cancers With 2 Complete Responses.23.10.2026 14:50:00 CEST | Press Release
Brenus Pharma, a clinical-stage biotech company, announced first data from the Phase Ia dose escalation of BreAK CRC-001. Nine unresectable patients were treated; 89% had liver metastases and 89% KRAS-mutant tumors, a population refractory to immunotherapy. Median follow-up: 8 months (1–14; data cut-off 6/08/2026). 95% of metastatic colorectal cancers are pMMR/MSS tumors, poorly immunogenic and resistant to immunotherapy. STC-1010, the company’s lead in vivo DC-engager, is designed to make these “cold” tumors visible to immune cells. Safety: no dose-limiting toxicity, only grade 1–2 related adverse events. Clinical activity (seven evaluable patients, RECIST 1.1): 100% disease control, 57% objective response rate (4/7). 43% of patients became operable (3/7): two with no evidence of disease afterward. Molecular profile: ctDNA dropped by up to 97% within two months, TP53 and KRAS mutations near undetectable. Immune activity (first six patients): STC-1010 regimen nearly quadrupled cytotoxi
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom